Vincristine‐induced neuropathy: Atypical electrophysiological patterns in children

Courtemanche, Hélène; Magot, Armelle; Ollivier, Yolaine; Rialland, Fanny; Leclair‐Visonneau, Laurène; Fayet, Guy; Camdessanché, Jean‐Philippe; Péreón, Yann

doi:10.1002/mus.24647

Cited by 39 publications

(35 citation statements)

References 16 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, dLUHMES cells were unique among the differentiating cell lines in being more sensitive than the undifferentiated LUHMES cells to 11 toxicants, including known neurotoxicants colchicine, methyl‐mercury (II), and vincristine. (Goldschmidt and Steward, ; Huang et al ., ; Courtemanche et al ., ). The greater sensitivity of the differentiating cells to so many compounds is unexpected, and may reflect sensitivity of specialized neurons to particular neurotoxicants observed in vivo .…”

Section: Discussionmentioning

confidence: 97%

Characterization of three human cell line models for high‐throughput neuronal cytotoxicity screening

Tong

Högberg

Kuo

et al. 2016

J of Applied Toxicology

View full text Add to dashboard Cite

More than 75,000 man-made chemicals contaminate the environment; many of these have not been tested for toxicities. These chemicals demand quantitative high-throughput screening assays to assess them for causative roles in neurotoxicities, including Parkinson’s disease and other neurodegenerative disorders. To facilitate high throughput screening for cytotoxicity to neurons, three human neuronal cellular models were compared: SH-SY5Y neuroblastoma cells, LUHMES conditionally-immortalized dopaminergic neurons, and Neural Stem Cells (NSC) from human fetal brain. These three cell lines were evaluated for rapidity and degree of differentiation, and sensitivity to 32 known or candidate neurotoxicants. First, expression of neural differentiation genes was assayed during a 7-day differentiation period. Of the three cell lines, LUHMES showed the highest gene expression of neuronal markers after differentiation. Both in the undifferentiated state and after 7 days of neuronal differentiation, LUHMES cells exhibited greater cytotoxic sensitivity to most of 32 suspected or known neurotoxicants than SH-SY5Y or NSCs. LUHMES cells were also unique in being more susceptible to several compounds in the differentiating state than the undifferentiated state; including known neurotoxicants colchicine, methyl-mercury (II), and vincristine. Gene expression results suggest that differentiating LUHMES cells may be susceptible to apoptosis because they express low levels of anti-apoptotic genes BCL2 and BIRC5/survivin; whereas SH-SY5Y cells may be resistant to apoptosis because they express high levels of BCL2, BIRC5/survivin, and BIRC3 genes. Thus, LUHMES cells exhibited favorable characteristics for neuro-cytotoxicity screening: rapid differentiation into neurons exhibiting high level expression neuronal marker genes, and marked sensitivity of LUHMES cells to known neurotoxicants.

show abstract

Section: Discussionmentioning

confidence: 97%

Characterization of three human cell line models for high‐throughput neuronal cytotoxicity screening

Tong

Högberg

Kuo

et al. 2016

J of Applied Toxicology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Vincristine neurotoxicity, commonly a peripheral sensorimotor neuropathy, is related to dose; and the presence of neurological signs has been reported in patients with ALL receiving a cumulative dose as low as 4.3 mg/m 2 , especially in younger children. 4 However, the clinical features of vincristine neuropathy have been variable. Some authors noted that the effects were reversible after discontinuation of treatment, 1,5,6 while others described permanent neurological sequelae, such as permanent loss of deep tendon reflexes, gross and fine motor deficits as well as handwriting difficulties.…”

Section: Introductionmentioning

confidence: 99%

Vincristine‐induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia

Tay

Lee

Ong

et al. 2017

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…17 One study noticed, in children the lower age could resulted in greater sensitivity of some nerves to vincristine and thus showing a motor predominant neuropathy in children. 18 Patients experiencing this side effects would require reduction or cessation of the chemotherapy. 11,19,20 Worst case that could happen is increase in cancerrelated morbidity and mortality.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of vincristine induced-peripheral neuropathy among Sudanese cancer patients

Imam¹,

Ibrahim²,

Palaian³

et al. 2016

JYP

View full text Add to dashboard Cite

Background: Increasing clinical evidence suggests treatment of cancer with neurotoxic agents results in some degree of peripheral neuropathy. Objective: The main objective of the study was to evaluate vincristine induced peripheral neuropathy among Sudanese cancer patients. Methods: A descriptive cross-sectional study was carried out at Radiation and Isotopes Center, Khartoum State, Sudan. All patients suffering from cancer with an age of 18 to 65 years were reviewed. A self-developed data collection form was used to collect the demographic data; drug use history; medical diseases; and vincristine cycles. The World Health Organization criteria were used to grade the side-effects. Data was collected for a period of two months and were analyzed descriptively. Results: Out of 78 patients reviewed, majority were females (n=47, 60.3%). Most of the patients were in the age group of 18-30 (n=27, 34.6%) and 51-60 (n=27, 34.6%) years. Twenty six (33.3%) of the patients took analgesic and 15.3% (n=12) experienced hypertension. Most of the patients went through more than 6 cycles of therapy with vincristine (n=24, 30.9%). Our study showed that 'altered bowel function (i.e constipation)' was the most important neuropathic change, which occurred in 62 (79.5%) of the patients who received vincristine. The second common neuropathic change was the 'lack of ability to go upstairs un-aided', which occurred in 37 (47.4%) of patients receiving vincristine. Majority of the patients (n=37, 47.5%) showed mild paresthesia as graded by the 'WHO grading scale'. Conclusion: More than three-fourth of the cancer patients experienced vincristine induced peripheral neuropathy. Healthcare professionals need some understanding regarding medical management that may decrease occurrence of neuropathy and a better planning and implementing special care for patients at risk.

show abstract

Vincristine‐induced neuropathy: Atypical electrophysiological patterns in children

Abstract: The electrophysiological and clinical motor predominance described differs from the mainly sensory neuropathy reported in adults. Incomplete myelination due to young age may have resulted in greater sensitivity of some nerves to neurotoxic agents.

Cited by 39 publications

References 16 publications

Characterization of three human cell line models for high‐throughput neuronal cytotoxicity screening

Characterization of three human cell line models for high‐throughput neuronal cytotoxicity screening

Vincristine‐induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia

Prevalence of vincristine induced-peripheral neuropathy among Sudanese cancer patients

Contact Info

Product

Resources

About